Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Mol Cell Biochem ; 476(9): 3219-3228, 2021 Sep.
Article in English | MEDLINE | ID: mdl-33866491

ABSTRACT

In developed countries, colorectal cancer (CRC) is the fourth most common cancer and the second leading cause of malignant-related deaths. CRC is treatable cancer when diagnosed early; however, diagnosis at the advanced stage is associated with a poor prognosis. Although chemotherapy is generally very promising, STAT3 protein which is overexpressed and persistently activated in CRC cells is observed to be the major contributor of chemoresistance development. It has been shown to play a prominent and pathogenic role in CRC initiation, progression, and metastasis. While over the past few years, research has been focused on STAT3 which is expressed at the center of various oncogenic pathways. This review is a discussion of the oncogenic role of STAT3 in CRC and potential therapeutic STAT3 inhibitors and analogs used to control and treat CRC.


Subject(s)
Antineoplastic Agents/therapeutic use , Colorectal Neoplasms/drug therapy , Molecular Targeted Therapy , STAT3 Transcription Factor/antagonists & inhibitors , Animals , Colorectal Neoplasms/metabolism , Colorectal Neoplasms/pathology , Humans
2.
Semin Cancer Biol ; 69: 69-76, 2021 02.
Article in English | MEDLINE | ID: mdl-31954835

ABSTRACT

Gastric cancer represents a deadly malignancy worldwide, yet current therapeutic regimens remain ineffective. Nanoparticle (NP) -based solutions could allow the design of novel therapeutic methods to eliminate this fatal disease. NPs typically carry out a significant role in multifunctional, multimodal imaging, and drug delivery carriers. In the recent decade, they have emerged as candidate approaches for the design of novel treatment strategies. Tumor nanotherapeutics characteristically possess various distinct advantages compared to conventional anti-cancer medications, which suffer from nonspecific bio-distribution, low solubility, and poor bioavailability. In this review, we will discuss the application of NPs in diagnosis and controlled drug delivery in gastric cancer (GC). We will focus on various NPs-based strategies employed against GC.


Subject(s)
Antineoplastic Agents/administration & dosage , Drug Delivery Systems , Multimodal Imaging/methods , Nanoparticles/administration & dosage , Stomach Neoplasms/drug therapy , Animals , Biological Availability , Humans , Nanoparticles/chemistry , Stomach Neoplasms/diagnostic imaging , Stomach Neoplasms/pathology
3.
Semin Cancer Biol ; 69: 178-189, 2021 02.
Article in English | MEDLINE | ID: mdl-31419527

ABSTRACT

Cancer is an outrageous disease with uncontrolled differentiation, growth, and migration to the other parts of the body. It is the second-most common cause of death both in the U.S. and worldwide. Current conventional therapies, though much improved and with better prognosis, have several limitations. Chemotherapeutic agents, for instance, are cytotoxic to both tumor and healthy cells, and the non-specific distribution of drugs at tumor sites limits the dose administered. Nanotechnology, which evolved from the coalescence and union of varied scientific disciplines, is a novel science that has been the focus of much research. This technology is generating more effective cancer therapies to overcome biomedical and biophysical barriers against standard interventions in the body; its unique magnetic, electrical, and structural properties make it a promising tool. This article reviews endogenous- and exogenous-based stimulus-responsive drug delivery systems designed to overcome the limitations of conventional therapies. The article also summarizes the study of nanomaterials, including polymeric, gold, silver, magnetic, and quantum dot nanoparticles. Though an array of drug delivery systems has so far been proposed, there remain many challenges and concerns that should be addressed in order to fill the gaps in the field. Prominence is given to drug delivery systems that employ external- and internal-based stimuli and that are emerging as promising tools for cancer therapeutics in clinical settings.


Subject(s)
Antineoplastic Agents/administration & dosage , Drug Delivery Systems , Nanomedicine , Nanoparticles/administration & dosage , Nanostructures/chemistry , Neoplasms/drug therapy , Animals , Humans , Nanoparticles/chemistry , Neoplasms/pathology
4.
Crit Rev Oncog ; 26(3): 43-51, 2021.
Article in English | MEDLINE | ID: mdl-35377985

ABSTRACT

Breast cancer (BC) is the most common cancer in women. Globally, the incidence of BC surpassed lung cancer for the first time in 2020, and it is highly heterogeneous. The tumor microenvironment (TME) of BC consists of blood vessels, fibroblasts, signaling molecules, immune cells, and extracellular matrix. Numerous studies have provided considerable evidence regarding the association between the circadian rhythm (CR) and human diseases. The CR induces remodeling of the TME cells and their components by disturbing the cellular metabolism, altering gene expression, and aberrantly activating signaling pathways. In this review we present the recent updates on the CR genes and their molecular mechanisms and signaling pathways. In addition, we present the mutations and single nucleotide polymorphisms in the CR genes and the CR pathways in BC biology and the management of the CR in patients with BC. The association between the CR and the TME in BC is also explored.


Subject(s)
Breast Neoplasms , Circadian Clocks , Breast Neoplasms/etiology , Breast Neoplasms/genetics , Circadian Clocks/genetics , Circadian Rhythm/genetics , Female , Humans , Polymorphism, Single Nucleotide , Tumor Microenvironment/genetics
5.
Mol Cell Biochem ; 472(1-2): 95-103, 2020 Sep.
Article in English | MEDLINE | ID: mdl-32562168

ABSTRACT

Protein-protein interactions (PPIs) are important biochemical processes that represent a major challenge in modern biology. Current approaches, which include high-throughput screening and computer aided ligand design, have limitations regarding the identification of hit matter. This current investigation focuses on computational study for protein-protein docking of hypoxia inducible factor-1α (HIF-1α), a tumor inducible factor, and Raf-1 kinase inhibitory protein (RKIP), a tumor metastasis suppressor. These are individually crystallized structures of interacting proteins, which interact to generate a conformational space. HIF activity in pancreatic tumors is determined by hypoxia and HIF-1α subunit availability. RKIP can be used as a prognostic indicator in a number of tumors. The interaction of RKIP with HIF-1α protects against pancreatic cancer (PC) metastasis by inhibiting its hypoxia function. We have explored the binding affinity between both the proteins with the HADDOCK (high ambiguity driven protein-protein docking) server, which determined that 158 structures in 11 clusters represent 79.0% of water-refined models. Of the best 10 clusters, the structures of cluster 2 were found to be better, as they had the lowest Z-score. Further supporting HIF-1α-RKIP interaction, pulldown assay has shown dissociation of RKIP from HIF-1α after CoCl2 treatment in both PC cell lines.


Subject(s)
Computational Biology/methods , Hypoxia-Inducible Factor 1, alpha Subunit/chemistry , Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Molecular Docking Simulation , Pancreatic Neoplasms/pathology , Phosphatidylethanolamine Binding Protein/chemistry , Phosphatidylethanolamine Binding Protein/metabolism , Protein Interaction Domains and Motifs , Crystallography, X-Ray , Humans , Pancreatic Neoplasms/metabolism , Protein Conformation
6.
Cancer ; 126(14): 3360-3371, 2020 07 15.
Article in English | MEDLINE | ID: mdl-32383803

ABSTRACT

BACKGROUND: The induction of reactive oxygen species (ROS) represents a viable strategy for enhancing the activity of radiotherapy. The authors hypothesized that napabucasin would increase ROS via its ability to inhibit NAD(P)H:quinone oxidoreductase 1 and potentiate the response to chemoradiotherapy in rectal cancer via distinct mechanisms. METHOD: Proliferation studies, colony formation assays, and ROS levels were measured in HCT116 and HT29 cell lines treated with napabucasin, chemoradiation, or their combination. DNA damage (pγH2AX), activation of STAT, and downstream angiogenesis were evaluated in both untreated and treated cell lines. Finally, the effects of napabucasin, chemoradiotherapy, and their combination were assessed in vivo with subcutaneous mouse xenograft models. RESULTS: Napabucasin significantly potentiated the growth inhibition of chemoradiation in both cell lines. Napabucasin increased ROS generation. Inhibition of ROS by N-acetylcysteine decreased the growth inhibitory effect of napabucasin alone and in combination with chemoradiotherapy. Napabucasin significantly increased pγH2AX in comparison with chemoradiotherapy alone. Napabucasin reduced the levels of pSTAT3 and VEGF and inhibited angiogenesis through an ROS-mediated effect. Napabucasin significantly potentiated the inhibition of growth and blood vessel formation by chemoradiotherapy in mouse xenografts. CONCLUSION: Napabucasin is a radiosensitizer with a novel mechanism of action: increasing ROS production and inhibiting angiogenesis. Clinical trials testing the addition of napabucasin to chemoradiotherapy in rectal cancer are needed.


Subject(s)
Benzofurans/administration & dosage , Chemoradiotherapy/methods , Naphthoquinones/administration & dosage , Radiation-Sensitizing Agents/administration & dosage , Rectal Neoplasms/metabolism , Rectal Neoplasms/therapy , Animals , Cell Proliferation/drug effects , Cell Proliferation/radiation effects , DNA Damage/drug effects , DNA Damage/radiation effects , HCT116 Cells , HT29 Cells , Humans , Mice , Mice, Nude , Neovascularization, Pathologic/metabolism , Reactive Oxygen Species/metabolism , Rectal Neoplasms/pathology , STAT3 Transcription Factor/metabolism , Signal Transduction/drug effects , Signal Transduction/radiation effects , Treatment Outcome , Tumor Burden/drug effects , Tumor Burden/radiation effects , Vascular Endothelial Growth Factor A/metabolism , Xenograft Model Antitumor Assays
7.
Curr Drug Metab ; 20(12): 958-966, 2019.
Article in English | MEDLINE | ID: mdl-31755384

ABSTRACT

BACKGROUND: The introduction of Monoclonal Antibodies (mAbs) and small-molecule Tyrosine Kinase Inhibitors (TKIs) that target the Epidermal Growth Factor Receptor (EGFR), marks a huge step forward in the Pancreatic Cancer (PC) therapy. However, anti-EGFR therapy is found to be successful only in a fraction of patients. Although anti-EGFR agents have shown considerable clinical promise, a serious adverse event associated with anti- EGFR therapy has been challenging. At this juncture, there is still more to be done in the search for effective predictive markers with therapeutic applicability. METHODS: A focused literature search was conducted to summarize the existing evidence on anti-EGFR agents in pancreatic cancer therapy. RESULTS: This review discusses various anti-EGFR agents currently in use for PC therapy and potential adverse effects associated with it. Existing evidence on EGFR TKIs demonstrated better tolerant effects and outcomes with multiple toxic regimens. Anti-EGFR therapy in combination with chemotherapy is necessary to achieve the best clinical outcomes. CONCLUSION: Future prospective studies on the identification of additional biological agents and novel anti-EGFR agents are warranted.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Pancreatic Neoplasms/drug therapy , Protein Kinase Inhibitors/therapeutic use , Antibodies, Monoclonal/adverse effects , ErbB Receptors/antagonists & inhibitors , Humans , Protein Kinase Inhibitors/adverse effects
8.
Crit Rev Oncog ; 24(2): 133-137, 2019.
Article in English | MEDLINE | ID: mdl-31679208

ABSTRACT

Pancreatic cancer (PC) is one of the most lethal forms of cancers, ranking as the third highest cause of malignancies and fatalities. Approximately 88% of patients diagnosed with PC are older than 55 yr. Due to PC's vague symptoms, patients typically visit their doctor only when they experience symptoms of extreme pain and/or after their bile ducts have blocked. This produces symptoms including darkly colored urine, jaundice, and light-colored stools. At this point in the progression of the disease, the tumor has already metastasized. Early detection of PC is critical and justifies the need for innovative techniques to efficiently aid in this process. Current research involves screening different aspects of the disease, imaging techniques, and evaluating blood, urine, cell, and saliva biomarkers. We propose that forensic DNA fingerprinting can be used to establish the role of genetics in PC, and we describe disease inheritance patterns so that relatives can understand the likelihood of developing this lethal malignancy.


Subject(s)
DNA Fingerprinting , Pancreatic Neoplasms/diagnosis , DNA, Mitochondrial , Early Detection of Cancer , Humans , Pancreatic Neoplasms/genetics
9.
Crit Rev Oncog ; 24(2): 139-148, 2019.
Article in English | MEDLINE | ID: mdl-31679209

ABSTRACT

Pancreatic cancer (PC) is the fourth leading cause of cancer deaths in both men and women. Because most PC patients are initially diagnosed at an advanced stage of disease, effective diagnostic tests for earlier diagnosis of PC are needed. Several studies have investigated the utility of nanoparticle for both diagnosis and therapy of PC. This review discusses the various engineered nanoparticles currently in use for imaging and therapy. Although nanoparticles have shown considerable clinical promise, complete translation of nanoparticle-based molecular imaging and oncotherapeutic agents has been the challenge.


Subject(s)
Drug Delivery Systems , Nanoparticles , Pancreatic Neoplasms/diagnostic imaging , Pancreatic Neoplasms/drug therapy , Humans , Pancreatic Neoplasms/therapy
10.
Crit Rev Immunol ; 39(4): 239-265, 2019.
Article in English | MEDLINE | ID: mdl-32421967

ABSTRACT

Autoimmune diseases occur when the body's natural defense system fails to differentiate its own cells from the foreign cells and mistakenly attacks the healthy cells. Among the autoimmune diseases, the most common serious disease is the type 1 diabetes (T1D). Biomarkers like c-peptide, autoantibodies, and glycated molecules are now widely used for the early diagnosis of diabetes. However, the diverse nature of biomarkers and the available autoantibodies as biomarkers are not enough to differentiate the heterogeneity inherent in T1D. Novel biomarkers have allowed the introduction of bioinformatics for assimilating the new data into clinical tools. Computer-aided drug design contributes to the discovery of novel autoantibodies, and molecular docking promises to enhance it. Moreover, the study of the pathophysiology of diabetes via molecular simulation has been proposed. In this review article, we focus on the characterization of the etiology, epidemiological factors, and mechanisms of hyperglycemia that induce cellular damage due to oxidative stress and proinflammatory responses. We also decribe novel biomarkers used for the detection of ß-cell destruction and diagnosis at early stages. Bioinformatics tools including molecular docking, sequence alignment, and homology modeling are also presented. This report supports researchers in drug design, in disease detection at an early phase, and in therapy development for T1D-associated complications.


Subject(s)
Diabetes Mellitus, Type 1/immunology , Immunotherapy/trends , Animals , Autoimmunity , Biomarkers , Computational Biology , Diabetes Mellitus, Type 1/epidemiology , Diabetes Mellitus, Type 1/physiopathology , Humans , Molecular Targeted Therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...